Abstract Beyond the hippocampus, there are no evidence-based dose constraints for eloquent structures which subserve memory and attention/processing speed. We performed a multivariate normal tissue complication probability analysis of post-RT neurocognitive decline, examining dosimetric predictors brain regions in prospective longitudinal clinical trial. 78 patients with primary tumors receivin...